Oracle France
Oracle France is recorded as a service provider in 9 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 9 of 9 trials · Latest update first
A phase 1/2a, first-in-human, open-label, dose-escalating study with a safety expansion cohort to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary anti-tumour activity of TAX2 in patients with relapsed/refractory advanced/metastatic solid tumours
Sponsor Apmonia Therapeutics
- Start (EU)
- Latest update
- Estimated end
- Not reported
A Phase I/II Open-Label, Multi-centre Study to Assess the Safety and Tolerability of Roginolisib in Combination with an Approved JAK Inhibitor in Patients with Myelofibrosis (MF) who are Unresponsive to JAK Inhibitors (HEMA-MED)
Sponsor iOnctura SA
- Start (EU)
- Latest update
- Estimated end
- Not reported
A Phase I/IIa Study of Roginolisib in combination with dostarlimab with or without docetaxel in patients with advanced non-squamous NSCLC who have progressed on standard of care immune checkpoint therapy and platinum doublet chemotherapy or standard immunotherapy without chemotherapy (PULMO-01).
Sponsor iOnctura SA
- Start (EU)
- Latest update
- Estimated end
- Not reported
An Open-Label, Phase 1 Dose-finding Study to Define the Maximum Tolerated Dose and Schedule of TRP-001 as Neoadjuvant Therapy in Treatment-naïve Very High-Risk Prostate Cancer Patients Eligible for Radical Prostatectomy with Extended Pelvic Lymph Node Dissection
Sponsor Torpedo Pharmaceuticals AG
- Start (EU)
- Not reported
- Latest update
- Estimated end
- Not reported
An Open-label, Multicenter, Phase 1/2a Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumour Activity of WEF-001 in participants with Advanced KRAS- Mutant Solid Tumours.
Sponsor Auricula Biosciences Inc.
- Start (EU)
- Not reported
- Latest update
- Estimated end
A Phase II, Multi-centre, Open label, Randomised Study to Evaluate the Anti-tumour Activity of Roginolisib (IOA-244) in Patients with Advanced/Metastatic Ocular/Uveal Melanoma
Sponsor iOnctura SA
- Start (EU)
- Latest update
- Estimated end
Impact of 18F-fluoroestradiol (FES) Positron Emission Tomography (PET) on the therapeutic treatment of patients with ER+ and HER2- metastatic breast cancer in relapse after first-line therapy combining hormone therapy
Sponsor GE Healthcare Limited
- Start (EU)
- Latest update
- Estimated end
- Not reported
An Open-label, Multicenter, Phase 1/2a Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumour Activity of WEF-001 in participants with Advanced KRAS- Mutant Solid Tumours.
Sponsor Auricula Biosciences Inc.
- Start (EU)
- Not reported
- Latest update
- Estimated end
A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of a 12-week administration of OATD-01, an oral inhibitor of chitinase-1 (CHIT1), for the treatment of active pulmonary sarcoidosis (the KITE study)
Sponsor Molecure S.A.
- Start (EU)
- Not reported
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Oracle France?
The 2026-10-09 snapshot links Oracle France to 9 distinct CTIS trials. Recorded services include Electronic data capture, eCRF, InForm eCRF (EDC), InForm eCRF (EDC) and RTSM, among 5 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Oracle France?
The most frequently recorded therapeutic areas are Solid Tumor Oncology, Dermatology, Gastroenterology, Gynecology. Recorded phases include Phase 1, Phase 2. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Oracle France conducted?
The linked trials record locations in 9 countries, including Spain, France, Italy, Belgium, Germany. These are trial locations, not confirmed office locations or countries where Oracle France delivered services.
What can this page tell me about Oracle France's trial experience?
Browse 9 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Oracle France. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Oracle France